Eli Lilly and Company: CEO History

Novo Nordisk's strengths are real and should not be underestimated: the company has manufactured insulin and diabetes drugs since 1923 (the same year Lilly first commercialized insulin in North America), its manufacturing capabilities have historically been more developed in the GLP-1 space, and Wegovy's clinical cardiovascular outcomes data from the SELECT trial — showing a 20 percent reduction in major cardiovascular events in patients with obesity and established cardiovascular disease — represents a landmark label claim that Lilly sought to match or exceed with tirzepatide's own cardiovascular outcomes program, the SURPASS-CVOT study, which also demonstrated significant cardiovascular risk reduction. What's often missed: Patent protection and the threat of generic and biosimilar competition represent structural long-term risks to Lilly's revenue model. While Lilly challenged the constitutionality of the program in federal court — a lawsuit that courts have largely not sustained — the company has also engaged constructively with the negotiation process, recognizing that Medicare market access is too important to sacrifice. Here's the thing — Clinical development risk remains inherent to the pharmaceutical business model. The company's Alzheimer's program illustrates this risk: after decades of failures in the space, donanemab received approval, but real-world uptake of Alzheimer's amyloid therapies has been slower than many analysts anticipated, constrained by the complexity of patient identification via amyloid PET imaging or cerebrospinal fluid testing, infusion center capacity, and reimbursement coverage decisions. Lilly threw its full manufacturing and scientific resources at the insulin problem.